HLA-DRB1 antibody
-
- Target See all HLA-DRB1 Antibodies
- HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))
-
Reactivity
- Human, Monkey
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This HLA-DRB1 antibody is un-conjugated
-
Application
- Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- Characteristics
- This mAb reacts with the beta-chain of HLA-DRB1 antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kDa alpha (heavy) chain and a 28 kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 Molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense cytoplasmic staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
- Purification
- Protein G affinity chromatography
- Immunogen
- Activated human peripheral blood mononuclear cells (LN-3 & HLA-DRB/1067) were used as the immunogen for the HLA-DRB1 antibody cocktail.
- Clone
- LN3-HLA-DRB-1067
- Isotype
- IgG2b kappa
- Top Product
- Discover our top product HLA-DRB1 Primary Antibody
-
-
- Application Notes
-
Optimal dilution of the HLA-DRB1 antibody cocktail should be determined by the researcher.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Western blot: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 0.25-0.5 μg/mL for 30 min at RT (1),Prediluted format : incubate for 30 min at RT (2) - Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
- Preservative
- Azide free
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store the HLA-DRB1 antibody cocktail at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
- Target
- HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))
- Alternative Name
- HLA-DRB1 (MHC II) (HLA-DRB1 Products)
- Synonyms
- MGC108235 antibody, DRB1 antibody, DRw10 antibody, HLA-DR1B antibody, HLA-DRB antibody, SS1 antibody, major histocompatibility complex, class II, DR beta 1 antibody, hla-drb1 antibody, HLA-DRB1 antibody
- Background
- This mAb reacts with the beta-chain of HLA-DRB1 antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kDa alpha (heavy) chain and a 28 kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 Molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense cytoplasmic staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
- Pathways
- TCR Signaling, Positive Regulation of Peptide Hormone Secretion, Production of Molecular Mediator of Immune Response, CXCR4-mediated Signaling Events, Cancer Immune Checkpoints
-